Evaluation of Abuse Potential of Synthetic Opioids and Other Depressants Using In Vivo Pharmacological Studies

The Drug Enforcement Administration (DEA) Headquarters, specifically the Diversion Control Division, Drug and Chemical Evaluation Section, is seeking a contractor to conduct in vivo pharmacological studies evaluating the abuse potential of synthetic opioids and other depressants. The contractor is responsible for performing investigational studies and providing the DEA with comprehensive results and detailed descriptions of the methodologies used. These findings support the agency's mission to evaluate drugs and chemicals to determine their potential for abuse.

This solicitation, identified by number 15DDHQ24R00000025, is classified under NAICS 611310 for Colleges, Universities, and Professional Schools and PSC R405 for Support- Professional: Operations Research/Quantitative Analysis. The performance of these services is based in Springfield, Virginia. Since the initial publication on April 19, 2024, the notice has been updated with five attachments, including a signed amendment addressing government responses to questions, a sample BPA call order, and a pricing sheet template.

Responses to this solicitation must be submitted by the deadline of May 17, 2024. The primary point of contact for this requirement is Darrell Goodwin. The procurement is being conducted as a full and open competition, as no specific set-aside was designated in the notice metadata.